Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
Insulin human
sanofi-aventis Deutschland GmbH
A10AB01
insulin human
Drugs used in diabetes
Diabetes Mellitus
Diabetes mellitus where treatment with insulin is required. Insulin Human Winthrop Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.
Revision: 15
Withdrawn
2007-01-17
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT _ _ Insulin Human Winthrop Rapid 100 IU/ml solution for injection in a vial 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 IU insulin human (equivalent to 3.5 mg). Each vial contains 5 ml of solution for injection, equivalent to 500 IU insulin, or 10 ml of solution for injection, equivalent to 1000 IU insulin. One IU (International Unit) corresponds to 0.035 mg of anhydrous human insulin. Insulin Human Winthrop Rapid is a neutral insulin solution (regular insulin). Human insulin is produced by recombinant DNA technology in _Escherichia coli_ . For the full list of excipients, see section 6.1. _ _ 3. PHARMACEUTICAL FORM Solution for injection in a vial. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Diabetes mellitus where treatment with insulin is required. Insulin Human Winthrop Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and post-operative stabilisation in patients with diabetes mellitus. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The desired blood glucose levels, the insulin preparations to be used and the insulin dose regimen (doses and timings) must be determined individually and adjusted to suit the patient’s diet, physical activity and life-style. _Daily doses and timing of administration _ There are no fixed rules for insulin dose regimen. However, the average insulin requirement is often 0.5 to 1.0 IU per kg body weight per day. The basal metabolic requirement is 40% to 60% of the total daily requirement. Insulin Human Winthrop Rapid is injected subcutaneously 15 to 20 minutes before a meal. In the treatment of severe hyperglycaemia or ketoacidosis in particular, insulin administration is part of a complex therapeutic regimen which includes measures to protect patients from possible severe complications of a relatively rapid lowering of blood glucose. T Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT _ _ Insulin Human Winthrop Rapid 100 IU/ml solution for injection in a vial 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 IU insulin human (equivalent to 3.5 mg). Each vial contains 5 ml of solution for injection, equivalent to 500 IU insulin, or 10 ml of solution for injection, equivalent to 1000 IU insulin. One IU (International Unit) corresponds to 0.035 mg of anhydrous human insulin. Insulin Human Winthrop Rapid is a neutral insulin solution (regular insulin). Human insulin is produced by recombinant DNA technology in _Escherichia coli_ . For the full list of excipients, see section 6.1. _ _ 3. PHARMACEUTICAL FORM Solution for injection in a vial. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Diabetes mellitus where treatment with insulin is required. Insulin Human Winthrop Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and post-operative stabilisation in patients with diabetes mellitus. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The desired blood glucose levels, the insulin preparations to be used and the insulin dose regimen (doses and timings) must be determined individually and adjusted to suit the patient’s diet, physical activity and life-style. _Daily doses and timing of administration _ There are no fixed rules for insulin dose regimen. However, the average insulin requirement is often 0.5 to 1.0 IU per kg body weight per day. The basal metabolic requirement is 40% to 60% of the total daily requirement. Insulin Human Winthrop Rapid is injected subcutaneously 15 to 20 minutes before a meal. In the treatment of severe hyperglycaemia or ketoacidosis in particular, insulin administration is part of a complex therapeutic regimen which includes measures to protect patients from possible severe complications of a relatively rapid lowering of blood glucose. T Lesen Sie das vollständige Dokument